GHK-Cu and skin: what the peptide-maxx crowd gets wrong

What's this video probably claiming?

Based on the caption and hashtags, @clarajensn is almost certainly attributing improved skin quality to GHK-Cu peptide use, while framing Tremfya (guselkumab, an IL-23 inhibitor biologic) as a trade-off that cleared her psoriasis but worsened acne. The "peptidemaxxing" hashtag situates this squarely in the self-optimization corner of TikTok where copper peptides are discussed as collagen boosters, wound-healing agents, and skin-regenerating compounds. The implied claim is likely something like: GHK-Cu topically or systemically improved her skin texture, tone, or healing capacity in a measurable way. She may also be suggesting that biologic therapy and peptide stacking work in complementary or competing ways on skin. Without a transcript we can't confirm exact wording, but the framing is consistent with dozens of similar creator narratives in this space.

What does the science actually show?

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) does have a legitimate, if limited, research base. Pickart et al. published extensively on copper peptide signaling through the 1990s and 2000s, showing GHK-Cu stimulates collagen and glycosaminoglycan synthesis in fibroblast cultures. A 2015 review by Pickart and Margolina in Organics summarized gene expression data suggesting GHK-Cu modulates over 4,000 genes involved in skin remodeling. That number is real, and also almost completely meaningless in isolation. In vitro gene expression changes do not translate linearly to clinical outcomes. Human RCT data is thin. A small 2001 study by Leyden et al. in JADS looked at a GHK-Cu-containing cream over 12 weeks and found modest improvements in fine lines compared to vehicle control, but effect sizes were not dramatic and the formulation variables make it hard to isolate the peptide. Systemic GHK-Cu via injection has essentially no peer-reviewed human safety or efficacy data in dermatology.

Where does the social media noise diverge from clinical reality?

The "peptidemaxxing" community treats GHK-Cu as if the fibroblast culture data is a prescription for glowing skin. It is not. There are real problems with this framing. First, bioavailability: topical copper peptides face significant skin barrier penetration challenges, and the concentration reaching dermal fibroblasts from a serum is not equivalent to what a cell culture study uses. Second, the Tremfya-acne connection the creator mentions is actually a documented side effect, with guselkumab trials reporting acne in roughly 1-2% of patients, so that part is pharmacologically coherent. But conflating a biologic's side effect profile with a peptide's purported benefits creates a false parallel, as if GHK-Cu is offsetting or competing with Tremfya's mechanisms. There is no clinical evidence for that interaction. Third, compounded injectable GHK-Cu sits in a regulatory gray zone and implying systemic use improved skin is an unverifiable and potentially unsafe claim.

What should you actually know?

If you are using a topical GHK-Cu product, the existing evidence weakly supports some skin texture benefit when formulated well, typically at concentrations around 0.1-1%, but the clinical effect size in humans is modest and the best studies are old and small. If a creator is implying injectable or systemic GHK-Cu fixed their skin, that claim has no credible human clinical backing and carries regulatory and safety concerns that should not be hand-waved away with a TikTok caption. Tremfya is an FDA-approved biologic with real clinical trial data behind it for moderate-to-severe plaque psoriasis, and its side effects including acne are documented in prescribing information. Mixing biologics with off-label peptide stacks without physician oversight is not a wellness optimization strategy. The wins and losses @clarajensn describes may be real subjective experiences. They are not evidence of mechanism.